Neoadjuvant immune checkpoint inhibition is gaining ground as a treatment strategy for early-stage, operable cancers. The list of potentially responsive tumor types now includes Merkel cell carcinoma; recent findings from an arm of the I-SPY2 trial also support the utility of this approach in HER2-negative breast cancer.

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.